El Kassas, M., N. Abdeen, D. Omran, M. Alboraie, M. Salaheldine, M. Eltabbakhe, R. Farghaly, M. Emadeldeen, shimaa afify, and A. Sweedy, "Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis", European Journal of Gastroenterology & Hepatology, vol. 33, issue 1S Suppl 1, pp. e877-e882., 2021.
Attallah, A. M., D. Omran, M. A. Abdelrazek, M. Hassany, S. Saif, R. E. E. Aza Farid3, R. E. Essawey, M. A. Ghaffar, M. Aabdelghany, and A. Yosry, "IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy", Journal of Genetic Engineering and Biotechnology, vol. 19, pp. 150-160, 2021.
Sepidarkish, M., G. Rezamand, M. Qorbani, H. Heydari, D. M. Estêvão, D. Omran, M. Morvaridzadeh, D. M. Roffe, F. Farsi, S. Ebrahimi, et al., "Effect of omega-3 fatty acids supplementation on adipokines: a systematic review and meta-analysis of randomized controlled trials", Crit Rev Food Sci Nutr . 2021 May 17;1-15, pp. 1-15, 2021.
Makhlouf, N. A., M. Abdel-Gawad, Aya M Mahros, S. A. Lashen, M. Zaghloul, A. Eliwa, E. E. Elshemy, Z. Ali-Eldin, D. Abdeltawab, F. El-Raey, et al., "Colorectal cancer in Arab world: A systematic review", World J Gastrointest Oncol, vol. 13, issue 11, pp. 1791-1798, 2021.
Mohamed, A. A., D. Omran, S. El-Feky, H. Darwish, A. E. L. Kassas, A. Farouk, O. Ezzat, S. M. Abdo, F. E. Zahran, A. El-Demery, et al., "Toll-like receptor 7 mRNA is reduced in hepatitis C-based liver cirrhosis and hepatocellular carcinoma, out-performs alpha-fetoprotein levels, and with age and serum aspartate aminotransferase is a new diagnostic index", Br J Biomed Sci . , vol. 78, issue 1, pp. 18-22. , 2021.
Gaafar, A. E., A. A. El-Aal, M. Alboraie, H. M. Hassan, adel el tahan, Y. Abdelrahman, M. - N. Wifi, D. Omran, A. himaa Mansour, W. M. Hassan, et al., "Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease", The Egyptian Heart Journal, vol. 71, issue 15, pp. 1-7, 2019.
application/pdf iconprevalence_of_prolonged_qt_interval_in.pdf
El Kassas, M., M. Alboraie, mervat naguib, H. Omar, adel el tahan, I. Moaz, M. Abdellah, S. Ezzat, M. - N. Wifi, A. F. Sherief, et al., "A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens", The Turkish Society of Gastroenterology, vol. 30, issue 8, pp. 708-13, 2019.
El Kassas, M., M. Alboraie, mervat naguib, H. Omar, adel el tahan, I. Moaz, M. Abdellah, S. Ezzat, M. - N. Wifi, A. F. Sherief, et al., "A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens", The Turkish Society of Gastroenterology, vol. 30, issue 8, pp. 708-13, 2019.
Attallah, A. M., D. Omran, M. M. Omran, M. S. Albannan, R. A. Zayed, S. Saif, A. Farid, M. Hassany, and A. Yosry, "Fibro-Mark: a panel of laboratory parameters for predicting significant fibrosis in chronic hepatitis C patients.", British journal of biomedical science, vol. 75, issue 1, pp. 19-23, 2018. Abstract

BACKGROUND: Fibrosis markers are useful for the prediction of cirrhosis but clinical scores such as King's score, AST-Platelet ratio index (APRI), Biotechnology research center (BRC), Fibrosis routine test (FRT), Fibro-α score and Fibro-quotient (FibroQ) have limited accuracy for diagnosing significant fibrosis. We hypothesised that new markers (reflecting the balance between hepatic fibrogenesis and fibrolysis) together with other indirect fibrosis markers would together construct a more sensitive and specific score capable of identifying fibrosis than existing scores.

METHODS: Collagen IV, hyaluronic acid, platelet-derived growth factor (PDGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured by ELISA, and AST, ALT, platelet count, albumin, total bilirubin, INR and AFP by routine methods in 148 patients with hepatitis C induced liver disease. Stepwise linear discriminant analysis and area under receiver-operating characteristic curves (AUCs) were used to create a predictive score and compare it to others.

RESULTS: Patients with significant fibrosis (n = 100, F2-F4) showed 2.08, 2.14, 1.80 and 1.90-fold increase in collagen IV, hyaluronic acid, PDGF and TIMP-1, respectively, over patients with no or mild fibrosis (n = 48, F0/F1)(all p < 0.01). Significant independent predictors of F2-F4 were AFP (AUC 0.79), age (0.76), PDGF (0.74), collagen IV (0.78) and TIMP (0.75), which together formed a five-marker score 'Fibro-Mark' for predicting F2-F4. In comparison with other scores, AUC for Fibro-Mark was 0.89, BRC was 0.83, followed by FRT and King's score (both 0.82), APRI (0.80), Fibro-α (0.70) and finally Fibro Q (0.63).

CONCLUSIONS: The Fibro-Mark score provides better discrimination in hepatic-fibrosis staging in chronic hepatitis C patients than existing scores.

Abdelaziz, A. O., M. M. Nabil, A. H. Abdelmaksoud, H. I. Shousha, M. B. Hashem, E. M. Hassan, A. Salah, D. A. Omran, and T. M. Elbaz, "Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.", European journal of gastroenterology & hepatology, vol. 31, issue 1, pp. 75-79, 2019. Abstract

INTRODUCTION: Scarce reports have commented on hepatocellular carcinoma (HCC) behavior after direct-acting antivirals (DAAs).

AIM: To analyze differences in tumor behavior between patients with hepatitis C virus (HCV)-induced HCC and were either treated or not using DAAs.

PATIENTS AND METHODS: This case-control study includes patients with HCV-related HCC who received generic DAAs (group I) and all non-DAA treated patients with HCC who presented to our clinic during the same period (group II). Patient and tumor characteristics, treatment types and outcome were compared between the two groups.

RESULTS: Group I included 89 patients and group II included 207 patients. No significant difference was detected between groups regarding HCC number or size. Group I showed a more infiltrative HCC pattern, whereas group II had more circumscribed and delineated lesions. The incidence of portal vein thrombosis and significant lymphadenopathy was significantly higher in group I (P=0.03 and 0.03, respectively). Serum levels of α-fetoprotein were significantly higher in group I (P=0.02). These factors significantly affected the response to HCC management (P=0.03). Incidence of complete responses were 47.2 and 49.8% for groups I and II, respectively, whereas incomplete responses were 12.4 and 25.1%, respectively. Supportive treatment was applied to 40.4% in group I and 25.1% in group II.

CONCLUSION: HCC behavior was more aggressive in DAA-treated patients regarding portal vein thrombosis, malignant lymphadenopathy, and HCC imaging characteristics, which affected the chance of ablation and the treatment response.